U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07685054) titled 'To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.' on June 28.
Brief Summary: This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or the combination of fimasartan, atorvastatin, and ezetimibe.
Study Start Date: Aug. 01
Study Type: OBSERVATIONAL
Condition:
Essential Hypertension
Primary Hypercholesterolemia
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Boryung Pharmaceutical Co....